Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fidia Spa ( (IT:FDA) ) has shared an announcement.
Fidia has reported a further step in the execution of its 2026 convertible bond loan reserved for Global Growth Holding Limited, with the conversion of five bonds from the fifth tranche into 5,000,000 new shares at a price of €0.01 per share. The new shares are admitted directly to trading, lifting the company’s share capital by €50,000 to €10,917,761.90 and increasing the total number of shares outstanding to 66,542,927.
With this latest conversion, the POC has been subscribed for a nominal €1,250,000, while €1,070,000 of the related capital increase has been subscribed, and 18 bonds from the fifth tranche remain to be converted. The transaction underscores the ongoing recapitalisation and financing process with GGHL, gradually strengthening Fidia’s equity base and potentially affecting its ownership structure and trading liquidity as further conversions occur.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.11 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
More about Fidia Spa
Fidia S.p.A., based in Turin and listed on Euronext Milan, is a global player in the design, production and marketing of high-performance integrated milling systems. Its solutions, including numerical controls, high-speed milling machines and CAM software for complex shapes, are used mainly in the automotive mould sector and the aerospace industry, positioning the group as a specialist across the entire milling process value chain.
Average Trading Volume: 1,696,314
Technical Sentiment Signal: Strong Sell
Current Market Cap: €496.7K
Find detailed analytics on FDA stock on TipRanks’ Stock Analysis page.